CAR T-Cell Therapy for ALL

Clinical Pearls

Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.

• Adult patients with relapsed ALL have a poor prognosis — overall survival is less than 10%.
• This CD-19-targeted CAR modified T-cell therapy elicited an 80% complete remission rate.
• The vast majority of these responses were MRD-negative.

<<<

Go back to the ASH conference page